Advarra
JUNE 20, 2023
Additionally, in 2021, a literature review estimated the average capitalized research and development (R&D) costs per new cancer medicine at between $944 million and $4.54 Typical clinical development timelines for anticancer drugs average an estimated 6.7 This means study startup times can vary greatly.
The Pharma Data
AUGUST 19, 2021
Oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2021 World Conference on Lung Cancer (WCLC) shows evidence that the bispecific mechanism of action for RYBREVANT TM can provide anti-tumor activity against either EGFR-mutated or MET-mutated non-small cell lung cancer. 8] , [9] , [10] , [11] , [12]. **In
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MAY 12, 2023
FSD Pharma has dosed the first cohort of patients in its Phase I clinical trial evaluating Lucid-MS for the treatment of multiple sclerosis (MS). Lucid-MS is a patented first-in-class, new chemical entity and a neuroprotective compound with a novel mechanism of action for the treatment of MS.
Drug Discovery World
FEBRUARY 22, 2024
With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.
Drug Discovery World
AUGUST 8, 2022
The company has been investigating Mim8 in its Phase I & II FRONTIER1 study and recently reported positive interim results from the study at the International Society of Thrombosis and Haemostasis Annual Congress (ISTH 2022) in London, UK. . Abstract presented at International Society of Thrombosis and Haemostasis (ISTH) 2022.
The Pharma Data
JULY 21, 2021
These data were shared as a late-breaking oral presentation during the virtual 11 th International AIDS Society Conference on HIV Science (IAS 2021) and are a follow-up to the interim analysis that was presented earlier this year at the virtual 2021 HIV Research for Prevention Conference (HIVR4P 2021). “The
The Pharma Data
AUGUST 29, 2020
3,4 LNP023 is currently in clinical development for PNH and a number of renal conditions with complement system involvement where significant unmet needs exist, including IgA nephropathy, complement 3 glomerulopathy (C3G), atypical hemolytic uremic syndrome and membranous nephropathy. Haematologica 2010;95(4):567–573.
Expert insights. Personalized for you.
52 
Let's personalize your content